跳至主要内容
临床试验/NCT00528671
NCT00528671终止4 期

Effects of Very Low Dose Oral Anticoagulation on Thromboembolism and Bleeding Events in Patients With Mechanical Heart Valve Replacement

Heart and Diabetes Center North-Rhine Westfalia1 个研究点 分布在 1 个国家目标入组 1,571 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
1,571
试验地点
1
主要终点
Thromboembolic events, Bleeding events, Survival rates

研究概览

简要总结

We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.

详细描述

In mechanical heart valve recipients, self-management of oral anticoagulation can reduce the risk of developing thromboembolic events and improves long-term survival compared with international normalized ratio (INR) control by a general practitioner. Low-dose INR self-management (INR values of 1.8.-2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients) does not increase the risk of thromboembolic events compared to conventional dose INR self-management. Even in patients with a low INR target range, however, the risk of bleeding events is still higher than the risk of thromboembolism. We therefore perform a prospective, randomized trial in 1,800 patients with mechanical heart valve replacement. During the first six postoperative months, low dose INR self-management will be performed by all patients (INR measurement once a week). Thereafter, 600 patients will continue with this treatment regimen, whereas the other 1,200 patients with perform very low dose oral anticoagulation. Out of these 1,200 patients, 600 will perform INR measurement once a week and 600 patients will perform INR measurement twice a week. Patients are followed up for 24 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mechanical heart valve recipients

排除标准

  • Contra-indication to phenprocoumon
  • Ulcerous disease with bleeding tendency,
  • Hypo- or hypercoagulability
  • Missing informed consent

研究组 & 干预措施

A

Active Comparator

Low dose oral anticoagulation, INR self-management once a week

干预措施: phenprocoumon (Drug)

B

Active Comparator

very low dose oral anticoagulation, INR self-management once a week

干预措施: phenprocoumon (Drug)

C

Experimental

very low dose oral anticoagulation, INR self-management twice a week

干预措施: phenprocoumon (Drug)

结局指标

主要结局

Thromboembolic events, Bleeding events, Survival rates

时间窗: 2 years

次要结局

  • INR values, Percent of INR values in the target range(2 years)

研究者

发起方
Heart and Diabetes Center North-Rhine Westfalia
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Very Low Dose Oral Anticoagulation and... | 临床试验